Background: Variable rate intravenous insulin infusion (VRIII) is an established method to achieve normoglycaemia in unwell or fasting patients. The Joint British Diabetes Societies (JBDS) released new guidance for the use of VRIII in medical inpatients in October 2014. This specifies the appropriate clinical circumstances in which a VRIII should be used and how it should be initiated, managed and discontinued safely. Methods: We developed an audit tool based on the guidelines and audited the current practice at the Royal Sussex County Hospital, Brighton, prior to the roll out of the new standards. We have audited 50 patients on VRIII under non-specialist medical and surgical care. Results: Several parameters were checked. VRIII prescription was signed appropriately as per the guidance in 98% of patients. Oral hypoglycaemic medications were omitted in 83%. Short-acting and mix insulins were omitted only in 88%. Long-acting insulin was administered only in 77% of the patients. Blood glucose was tested 1-2 hourly in 90% of patients. All patients with hypoglycaemic episodes were treated as per protocol. On the occasions where VRIII was discontinued, it was reinitiated within 20 min as per the guidelines only in 36% of cases. In patients with persistent hyperglycaemia, the rate was increased in 80% of cases. Discussion: Clinical practice surrounding the use, appropriate management and monitoring parameters appeared to fall short of the standards suggested by the latest JBDS guidance. Our audit outcome was to prepare a protocol for the trust summarising the indications for VRIII, target capillary blood glucose, how and when to stop VRIII for patients with diabetes and also a prompt to prescribe basal insulin for patients with diabetes and when a referral should be made to the diabetes inpatient team. Intro-
Introduction
Approximately 15% of hospital inpatients have diabetes, of which 70% are admitted as medical emergencies; the majority have diabetes as a secondary diagnosis. 1 There is good evidence from both medical and surgical settings to indicate that, if blood glucose is not controlled, the outcomes measured by mortality, morbidity or length of stay are suboptimal. Variable rate intravenous insulin infusion (VRIII) or sliding scales have been used for many years as an effective mechanism of adjusting and controlling blood glucose levels in the hospital setting. It is well recognised that there is no such thing as one perfect sliding scale, 2 but it does provide a good system of stabilising a patient's diabetes following the inter-current stresses of medical illness, surgery and metabolic imbalance. 3, 4 Results from the National Diabetes Inpatient Audit over recent years have demonstrated that there is a great deal of variation in practice around the use of VRIII in terms of the appropriateness of its use, the individualised settings, its duration and effectiveness and the recurrent problem of general nursing and medical staff's reluctance to continue the administration of basal insulin alongside the insulin infusion. 5 The previous National Diabetes Inpatients Audit results from 2013-14 demonstrated 5 : 1 Inappropriate VRIII use: 6.5% of patients were thought to have been treated with a VRIII unnecessarily. 2 Inappropriate duration of use: 10.6% of inpatients with diabetes received an insulin infusion during the previous 7 days, of whom 7.8% were treated with an insulin infusion for 7 days or longer; 7.7% of insulin infusions were deemed unnecessarily long by the diabetes team. We wished to focus on the processes that are followed with regard to the use of VRIII. This present audit therefore provides a snapshot of current practice within our trust to look at our baseline level of compliance with the JBDS standards prior to them being rolled out. This was in order to identify where the deficits lay and to help inform service improvement. It also provides the opportunity to critique the guidance when applied to day-to-day clinical activity.
Methods
A retrospective observational approach was used to gather data on the use of VRIII within our hospital trust. Local audit registration and governance procedures were followed. Data collection took place over a 12-week period. Adult patients under nonspecialist care were included and there were no obvious exclusion criteria as we wanted to assess the clinical management of as many patients as possible. We developed an audit tool ( Figure  1 ) based on these guidelines and audited the current practice at the Royal Sussex County Hospital, Brighton.
Results
Fifty patients in the inpatient setting who were on VRIII for a variety of reasons were audited. Their mean age was 62 years; 80% were male and 20% were female. Of these patients, 4% had a new diagnosis of type 1 diabetes and 42% were already known to have type 1 diabetes. Similarly, 4% of the patients had a new diagnosis of type 2 diabetes and 56% of patients were known to have type 2 diabetes, 32% of whom were treated with insulin. Indications for the use of VRIII are listed in table 1.
Appropriate set-up VRIII prescription was signed appropriately as per the guidance in 98% of patients. Oral hypoglycaemic medications were omitted in 83%. Short-acting and mix insulins were omitted in 88% of patients. Basal/long-acting insulin was administered only in 77% of the patients. Capillary blood glucose was tested 1-2 hourly in 90% of patients whilst on VRIII.
Management of dysglycaemia
All patients with hypoglycaemic episodes were treated as per the trust protocol. On the occasions where VRIII was discontinued, it was reinitiated within 20 min as per the guidelines in only 36% of cases (this is deemed necessary in order to prevent rebound hyperglycaemia). Two patients had persistent hypoglycaemia; the insulin rate was reduced only in one case. In patients with persistent hyperglycaemia, the rate was appropriately increased in 80% of cases.
Fluid and electrolyte status
Fluid status was noted and fluid balance charts were documented in only 52% of patients. 78% of patients had daily renal function and electrolyte check (92% of medical and 63% of surgical patients). In two-thirds of patients (66%) the need to continue the VRIII was appropriately re-assessed and documented in the medical records. None of the patients had VRIII for more than 7 days in total.
Discontinuing VRIII 80% of patients were weaned off VRIII when eating and drinking. Two patients were on nasogastric feeds. 82% of patients had stable THE BRITISH JOURNAL OF DIABETES 26 capillary blood glucose (CBG) when switched to subcutaneous insulin. 85% of them were weaned off at a meal time as per the best practice guidance. Basal insulin was given prior to switching off VRIII in 84% of patients on average. Short-acting insulin and oral hypoglycaemic medications were restarted prior to switching from VRIII in 52% of cases. CBG was monitored 1 h after stopping VRIII (which is also part of the protocol) in only 58% of patients. In summary, the major deviations from meeting the JBDS standards related to issues with appropriate use and duration of VRIII; failure to continue basal insulin; failure to restart a sliding scale after hypoglycaemia; suboptimal monitoring and documentation of fluid status and renal function; insufficient clarity and documentation over the continuance of VRIII; and poor practice around the weaning/discontinuation of VRIII.
Discussion
The recent JBDS guidance provides a clear and thorough approach to the safe and sensible use of an insulin sliding scale. This is especially important as several observational studies point to a strong association between hyperglycaemia and poor clinical outcomes, including prolonged hospital stay, infection, disability after discharge from hospital and death. [7] [8] [9] We were keen to assess our current hospital practice as part of projects to improve inpatient diabetes care in Brighton, 10 and much of the JBDS guidance is a remarkable route to best practice ( Figure 2 ).
It would appear that there is failure to achieve high rates of concordance on several of the dimensions relating to safe and effective VRIII usage when assessed in detail in this present audit. One major recurring factor appears to relate to the appropriateness of VRIII use in the context of dysglycaemia when another management strategy may be more appropriate. These, like other failings in its successful utilisation, most likely relate to insufficient knowledge and understanding. Similarly, the failure to continue basal insulin alongside VRIII can have an effect on outcomes, and both education and alterations to systems and processes can help overcome this. It is apparent that overall practice in the clinical setting in relation to meeting the standards of VRIII usage is suboptimal within this small cohort of inpatients. Lessons need to be learnt and shared with the relevant inpatient teams, nurses, pharmacists and patients themselves. Whilst concordance is close to best practice in several areas, there are some specific problems that have been identified as being in need of improvement. When rolling out the new JBDS guidance, the aim is to deal with these in terms of changes to processes, but also via remedial education for all those involved in prescribing and administering, as 'trying harder' or 'more training' do not always work on their own in relation to multi-systems improvement. 11 Potential explanations for the above problems • General lack of understanding of the principles and pathophysiology of diabetes and insulin action amongst nursing and medical staff. • Failure of clarity over the use and utility of VRIII.
• Traditional over-reliance on the inpatient diabetes nursing team to come and sort out diabetes problems.
• Lack of dedicated inpatient diabetes consultant sessions.
• Failure to make inpatient diabetes/glycaemic control management mandatory for junior doctors at trust induction.
• Failure to properly utilise the network linked glucose meter technology. Our audit outcomes were therefore to prepare a protocol for the trust summarising the indications of VRIII, target CBGs, how and when to stop VRIII for patients with diabetes and to explore options for including this as part of both junior doctor and nursing training occurring at induction and on a ongoing statutory / mandatory basis.
Secondly, a prompt to prescribe basal insulin for patients with diabetes and when a referral should be made to the diabetes inpatient team, as well as an update to the current Trust-wide inpatient insulin prescribing and administration chart (VRIII section) needs to be considered. This may ultimately become more practical when electronic prescribing systems come into action in the 'near' future. Introducing a teaching session to all the professionals and raising awareness through a hospital-wide communication programme on the wards would also theoretically improve the results, 12 as would the introduction of a dedicated 'Diabetes link' nurse in each of the major ward areas as part of a wider hospital diabetes improvement programme. The effect of such changes can be evaluated in future re-audits once the new guidance is implemented.
Criticisms of the JBDS guidance
It is difficult to find fault with the JBDS guidance itself, which is well thought out and comprehensive. Because of the problems identified in this audit and the fact that the majority of people with diabetes in the hospital setting are looked after by nondiabetologists, it would seem sensible -if not horribly reductionist -to produce and issue an even more abbreviated best practice guide for nurses, healthcare assistants and foundation doctors which can be accessed and referred to with ease, similar perhaps to the laminated cards used in many NHS hospital trusts which summarise microbiology guidance. An example of a comprehensive VRIII checklist is shown in Figure 3 . Additionally, one may consider whether the necessity of a daily electrolyte check is essential in all cases (although the use of concurrent insulin and fluids necessary with a VRIII increases the risk of electrolyte disturbance). There should also be some reflection of patient factors to consider the individual at the centre of care and incorporate the concept of insulin self-administration and monitoring in parallel to develop a shared approach to inpatient diabetes management. This may necessitate the use of a joint monitoring document and a competency assessment to ensure safety and compliance (e.g., in the situation where basal insulin or mealtimes boluses continue to be given during VRIII usage).
Conclusions
The majority of patients on VRIII are managed by non-diabetic teams and practice may vary from set guidance due to unfamiliarity and lack of diabetes-specific knowledge. The appropriate use of VRIII needs to be tackled through remedial education, allied to improvements in systems and processes.
The JBDS standards themselves are good and relate to the real world. Refinements for future versions could include simplification for the non-specialist, removal of some non-essential processes and the inclusion of patient input/joint management for those who are able. It still remains the case that patients often know far more about their diabetes than the medical staff looking after them.
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Key messages
• Insulin sliding scales can be a common source of inpatient error due to misprescribing, misunderstanding and inappropriate use • The JBDS have developed new guidance on the straightforward use of VRIII in order to reduce variation in clinical practice • Our baseline audit of practice before implementation of the new guidelines demonstrated much work needs to be done in terms of extra education and changes to systems and processes -the more data, the more complete our understanding of this new treatment will be -all contributors will be listed in publications arising from data submission l you are able to analyse your local data easily l you are invited to enter your patients' data into the online tool on N3 (the NHS secure network) l the data will be automatically added to the national data in anonymised form l we can provide easy-to-complete paper proformas for use in clinic if preferred
Does your centre use dapagliflozin (Forxiga)?
If yes, REGISTER YOUR CENTRE! by contacting abcd.audits@diabetologists.org.uk
Please remember:
ABCD launched a nationwide audit of dapagliflozin in the UK.
This audit is particularly important with dapaglifozin being the first of a new class of drugs for diabetes, the SGLT2 inhibitors. We have a chance to assess real clinical efficacy and safety of this new type of treatment by pooling our experience nationwide Dapagliflozin (Forxiga) Nationwide Audit in progress
